論文・技術情報追加のお知らせ

1. Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database.

デノスマブは低カルシウム血症のリスクが高い

対象DB：FAERS

2. Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System.

カルバマゼピンは多様な副作用があり、注意が必要

対象DB：FAERS

3. Adverse events associated with parenteral nutrition support therapy: A pharmacovigilance study.

経腸栄養は肝胆道障害などのリスクがある

対象DB：FAERS

4. Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system.

レベチラセタムは横紋筋融解症のリスクを増加させる

対象DB：FAERS

5. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine.

ゲムシタビンは多くの有害事象を引き起こす可能性がある

対象DB：FAERS

6. Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database.

スタチン使用は免疫関連有害事象のリスクを増加させる

対象DB：FAERS

7. The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).

DXM/BUPはアルコールや薬物乱用の報告なし。FDA承認時の依存性なしと一致

対象DB：CVAR,FAERS

8. Adverse events analysis of Relugolix (Orgovyx(R)) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS).

リルゴリクスの有害事象をFAERSで分析、ポラキウリアや前立腺特異抗原増加が新たな副作用

対象DB：FAERS

9. Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).

トリプタンは心血管有害事象リスクがあり、特にスマトリプタンが高い

対象DB：FAERS

10. Mining and analysis of adverse event signals for alendronate based on the real-world data of FDA adverse event reporting system database.

アレンドロン酸関連の有害事象が多数検出され、さらなる研究が必要

対象DB：FAERS

11. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase(R)).

GLP-1 RAに関する自殺関連のリスクが混在。因果関係は不明

対象DB：CVAR,FAERS,VigiBase

12. Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System.

NDRI薬剤の心血管副作用を分析し、安全性を強調

対象DB：FAERS

13. Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.

緑内障治療におけるプロスタグランジンの副作用をFAERSで評価

対象DB：FAERS

14. A Clustering Ensemble Method for Drug Safety Signal Detection in Post-Marketing Surveillance.

市販後の薬剤安全性を監視するためのクラスタリング手法を提案

対象DB：FAERS

15. Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database.

オキサリプラチンは眼の有害事象を引き起こす可能性があり、重篤な症例が多い

対象DB：FAERS

16. Ocular adverse events associated with GLP-1 receptor agonists: a Real-World Study Based on the FAERS database and network pharmacology.

GLP-1受容体作動薬は眼の有害事象のリスク増加

対象DB：FAERS

17. A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system.

タファシタマブに関連する有害事象をFAERSで分析

対象DB：FAERS

18. Evaluation of beta-Blocker-Induced Bradyarrhythmia Using an Analysis of the Japanese Adverse Drug Event Report Database.

β遮断薬による徐脈は治療開始後2か月以内に多く発生

対象DB：JADER

19. Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database.

糖尿病患者におけるケトアシドーシスの報告が多い

対象DB：EudraVigilance

20. Lower reporting of venous thromboembolisms events with natural estrogen-based COCs compared to ethinylestradiol containing pills: A disproportionality analysis of the Eudravigilance database.

自然エストロゲン製剤は血栓リスクが低い

対象DB：EudraVigilance

21. Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase).

ロペラミドはイリノテカンの副作用リスクを増加させる

対象DB：VigiBase

22. Lipschutz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.

COVID-19ワクチン接種後にリプシュッツ潰瘍が報告、若年女性に注意

対象DB：VigiBase

23. Ischemic cardiopathy induced by capecitabine in gastric cancer: The role of dihydropyrimidine dehydrogenase metabolites.

胃癌患者におけるカペシタビンの心筋虚血リスク、DPD代謝物が関与

対象DB：FPVD,VigiBase

24. Global burden of vaccine-associated Guillain-Barre syndrome over 170 countries from 1967 to 2023.

ワクチン関連のギラン・バレー症候群の報告増加、高齢者がリスク

対象DB：VigiBase

25. Current status analysis of the prevalence and regional disparities of robot-assisted laparoscopic prostatectomy in Japan using diagnosis procedure combination data.

日本でのロボット手術導入に地域差、都市部が優位

対象DB：DPC

26. Body mass index is associated with disability at discharge as indicated by the modified Rankin Scale in patients with ischemic stroke: a JROAD-DPC study.

BMIと脳梗塞障害にU字型の関係が確認された

対象DB：DPC

27. Temporal trends and practice variation of paediatric diagnostic tests in primary care: retrospective analysis of 14 million tests.

小児診断検査が増加し、診療所間でばらつきあり

対象DB：CPRD

28. Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration.

認知症薬と加齢黄斑変性のリスクに有意差なし

対象DB：CPRD

29. Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study.

英国で肺がんの罹患率と生存率が増加、特に高齢女性

対象DB：CPRD

30. Bayesian blockwise inference for joint models of longitudinal and multistate data with application to longitudinal multimorbidity analysis.

複雑なイベント履歴データを扱うベイズ推論法を提案し、計算効率を向上

対象DB：CPRD